SGCB and chronic thromboembolic pulmonary hypertension: The sGC stimulator riociguat, has recently undergone Phase III clinical trials in patients with several subforms of pulmonary arterial hypertension (PAH) and with chronic thromboembolic pulmonary hypertension (CTEPH).